These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22579612)

  • 1. The role of angiotensin II in nonalcoholic steatohepatitis.
    Matthew Morris E; Fletcher JA; Thyfault JP; Rector RS
    Mol Cell Endocrinol; 2013 Sep; 378(1-2):29-40. PubMed ID: 22579612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
    Georgescu EF
    Adv Ther; 2008 Nov; 25(11):1141-74. PubMed ID: 18972077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
    Bosserhoff A; Hellerbrand C
    Dig Dis; 2011; 29(4):377-83. PubMed ID: 21894008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
    Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of aldosterone and angiotensin II in insulin resistance: an update.
    Lastra-Lastra G; Sowers JR; Restrepo-Erazo K; Manrique-Acevedo C; Lastra-González G
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):1-6. PubMed ID: 19138313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.
    Salt WB
    J Insur Med; 2004; 36(1):27-41. PubMed ID: 15104027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction.
    Jing F; Mogi M; Horiuchi M
    Mol Cell Endocrinol; 2013 Sep; 378(1-2):23-8. PubMed ID: 22465098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.
    Fracanzani AL; Valenti L; Bugianesi E; Vanni E; Grieco A; Miele L; Consonni D; Fatta E; Lombardi R; Marchesini G; Fargion S
    J Hepatol; 2011 Jun; 54(6):1244-9. PubMed ID: 21145841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
    Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fibrogenesis and metabolic factors.
    Anty R; Lemoine M
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S10-20. PubMed ID: 21742296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
    Sanyal AJ
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD.
    Boursier J; Chaigneau J; Roullier V; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Deugnier Y; Rousselet MC; Cavaro-Ménard C; Gallois Y; Aubé C; Calès P;
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):974-81. PubMed ID: 21904208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Tiniakos DG
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [RAAS and insulin resistance].
    Motoshima H; Araki E
    Nihon Rinsho; 2012 Sep; 70(9):1542-9. PubMed ID: 23012801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fatty liver and global cardiometabolic risk].
    Szollár L
    Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.